共 103 条
- [21] Report of the Committee on Infectious Diseases, 29th Edition. Editor: Larry K. Pickering, MD, FAAP
- [22] Associate Editors: Carol J. Baker, MD, FAAP
- [23] David W. Kimberlin, MD, FAAP
- [24] Sarah S, (2012)
- [25] Samson L., Prevention of respiratory syncytial virus infection, Paediatr Child Health, 14, pp. 521-532, (2009)
- [26] Figueras-Aloy J., Carbonell-Estrany X., de Estandares de la SENeo C., Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial, An Pediatr, 82, 199, pp. e1-e2, (2015)
- [27] Bollani L., Baraldi E., Chirico G., Dotta A., Lanari M., Del V.A., Et al., Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital, J Pediatr, 41, (2015)
- [28] Bont L., Checchia P., Fauroux B., Figueras-Aloy J., Manzoni P., Paes B., Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries, (2016)
- [29] Oxford Centre for Evidence-Based Medicine
- [30] Oxford Centre for Evidence-Based Medicine